Professor Thomas Powles, Barts Cancer Institute, London discusses the impact of immunotherapy on the treatment of kidney cancer.

There has been an enormous change in the treatment of kidney cancer in 2017 with studies of immunotherapy in the frontline setting, says Powles. CheckMate-214 is the study credited with potentially changing the frontline treatment of this disease, demonstrating a reduced risk of death of 32% with the combination on nivolumab (Opdivo) and ipilimumab (Yervoy) compared with sunitinib (Sutent).

See Professor Powles’ short video here